Acquired Haemophilia Pipeline Analysis 2018 - Focus on Clinical Trials and Results, Drug Profiling, Patents, and Collaborations - ResearchAndMarkets.com

DUBLIN--()--The "Acquired Haemophilia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

The report covers more than 10 drugs currently in different phases of development.

The report provides acquired haemophilia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Major industry players profiled as part of the report are Pfizer Inc., Bayer AG, Shire, CSL and Genentech, Inc. among others.

Scope

  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration

Key Topics Covered

1. Introduction

1.1. Research Methodology

1.2. Research Scope

2. Disease Overview

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

  • Drug Name
  • Generic Name
  • Synonyms
  • Company
  • Collaborator
  • Route of administration
  • Target
  • Mechanism of Action
  • Technology
  • Molecule type
  • CAS Number
  • Weight
  • Chemical Formula
  • IUPAC name
  • ATC code

5.3. By Molecule Type

5.4. Analysis by Region

6. Company Profiling

6.1. Shire

6.2. Novo Nordisk A/S

6.3. Genentech, Inc.

6.4. CSL

6.5. rEVO Biologics, Inc

6.6. OPKO Health Inc.

6.7. REGENXBIO Inc.

6.8. Pfizer Inc.

6.9. Bayer AG

6.10. Bioverativ

6.11. HEMA Biologics, LLC

6.12. Catalyst Biosciences

For more information about this report visit https://www.researchandmarkets.com/research/gb6nrp/acquired?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials